For laboratory research use only. This article summarises published preclinical and in vitro literature. GHK-Cu is not approved for human use in the UK or any other jurisdiction and is sold by Velyx Research Ltd strictly as a research compound.
What is GHK-Cu?
GHK-Cu is a naturally occurring copper-binding tripeptide complex consisting of three amino acids — glycine, L-histidine, and L-lysine — chelated to a copper(II) ion. Its systematic name is glycyl-L-histidyl-L-lysine copper(II) complex. The molecular formula of the GHK tripeptide is C₁₄H₂₃N₆O₄ with a molecular weight of 340.37 daltons; in its copper-chelated form (GHK-Cu) the molecular weight is approximately 403.91 daltons. Its CAS registry number is 49557-75-7.
The peptide was first isolated from human plasma albumin in 1973 by biochemist Dr. Loren Pickart, then at the University of California San Francisco, during research into why plasma from young adults (aged 20–25) stimulated markedly different protein synthesis patterns in aged liver tissue compared to plasma from older donors. Pickart identified the active fraction and, after four years of further investigation, isolated the tripeptide responsible, publishing the finding in 1977. He would spend the next four decades expanding the research into what became one of the most extensively studied naturally occurring peptides in the biological sciences.
GHK occurs naturally in human plasma, saliva, and urine. It is also present as an embedded sequence within the alpha-2(I) chain of Type I collagen — a structural detail that carries biological significance, as proteolytic breakdown of collagen at wound sites releases GHK directly into the tissue microenvironment, where it can act as an endogenous repair signal. This is one of the reasons GHK-Cu has attracted sustained research interest: unlike many research compounds, it is a molecule the body already produces and deploys in response to injury.
Plasma GHK levels decline substantially with age. Published data indicates levels of approximately 200 ng/mL in young adults aged 20–25, falling to roughly 80 ng/mL by age 60. This age-related decline has made GHK-Cu a compound of particular interest to researchers investigating the biology of ageing, tissue repair capacity, and longevity mechanisms.
GHK-Cu is not approved for clinical or therapeutic use by any regulatory authority, including the MHRA in the UK. It is sold by Velyx Research Ltd exclusively as a research compound for laboratory use and is not for human or veterinary consumption.
Molecular Structure and the Role of Copper
Understanding GHK-Cu requires understanding what the copper ion contributes, because it is not incidental — it is mechanistically central to the compound's documented biological activity.
Copper is a transitional metal essential to all eukaryotic life. Because it can alternate between oxidised Cu(II) and reduced Cu(I) states, it functions as an electron transfer cofactor in numerous enzymatic reactions. A dozen enzymes — cuproenzymes — use changes in copper oxidation states to catalyse important biochemical reactions, including cellular respiration via cytochrome c oxidase, antioxidant defence via ceruloplasmin and superoxide dismutase, detoxification via metallothioneins, blood clotting via factors V and VIII, and connective tissue formation via lysyl oxidase.
Lysyl oxidase is particularly relevant to GHK-Cu's documented effects on connective tissue. This enzyme catalyses the cross-linking of collagen and elastin fibres — the process that gives mature collagen its tensile strength and structural integrity. Without adequate copper supply, lysyl oxidase activity is impaired and newly synthesised collagen fibres fail to cross-link properly, resulting in structurally weak matrix. GHK-Cu's role as a copper delivery vehicle to tissue sites — particularly wound environments where copper availability may be locally depleted — is one proposed mechanism by which it supports organised extracellular matrix formation.
The tripeptide sequence itself has high affinity for Cu(II) ions, with the imidazole ring of histidine and the terminal amino groups of glycine and lysine forming the coordination complex. This copper-chelating property means GHK can function both as a copper chaperone — transporting and releasing copper where enzymatic demand is high — and as an antioxidant, sequestering free copper ions that would otherwise catalyse harmful Fenton reactions generating hydroxyl radicals.
Molecular Mechanisms: How GHK-Cu Acts on Cells
Unlike most signalling molecules that operate through a single defined receptor or pathway, GHK-Cu has been shown across the published literature to modulate multiple biological processes simultaneously. This breadth of activity was initially puzzling to researchers but has become better understood through large-scale gene expression analysis.
Extracellular Matrix Synthesis and Remodelling
The foundational mechanism in GHK-Cu research is its effect on fibroblast-mediated extracellular matrix (ECM) production. Maquart et al. (1988), publishing in the Journal of Clinical Investigation (PMID: 3169264), demonstrated that GHK-Cu stimulated collagen synthesis in fibroblast cultures beginning at concentrations between 10⁻¹² and 10⁻¹¹ M, with maximum stimulation at 10⁻⁹ M — nanomolar concentrations. Critically, the effect was independent of any change in cell number, indicating the mechanism is one of enhanced synthetic activity per cell rather than simple proliferation.
This collagen-stimulating effect has been replicated and extended across multiple independent research groups. In human dermal fibroblast models, GHK-Cu has been documented to upregulate both Type I collagen (COL1A1) and Type III collagen (COL3A1) — the two fibrillar collagens that provide the structural backbone of connective tissue. Type I collagen provides tensile strength; Type III collagen contributes flexibility and is the dominant form in early-stage wound repair before being progressively replaced by Type I during tissue maturation.
Beyond collagen, GHK-Cu increases production of elastin, decorin (a small leucine-rich proteoglycan that regulates collagen fibrillogenesis), and glycosaminoglycans — all structural components of the ECM that together determine tissue architecture, elasticity, and water retention capacity.
Critically, GHK-Cu does not simply stimulate matrix production without regulation. GHK-Cu does both, in balance — collagen I and III production goes up, elastin, decorin, and glycosaminoglycan synthesis increase, while simultaneously MMP activity gets regulated alongside their inhibitors (TIMPs). Too much building produces fibrosis. Too much breakdown and tissue falls apart. GHK-Cu supports organised remodelling rather than either extreme. This balanced regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) distinguishes GHK-Cu mechanistically from simple growth factor-mediated collagen stimulation, and is one reason it has attracted interest in both wound healing and anti-fibrotic research contexts.
Angiogenesis via VEGF and FGF-2 Signalling
GHK-Cu at a concentration of 1nM has been demonstrated to upregulate basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) expression in irradiated human dermal fibroblasts — both growth factors central to new vessel formation and restoration of blood flow in damaged tissue. GHK-Cu has additionally been shown to stimulate human umbilical vein endothelial cell (HUVEC) proliferation through VEGF and FGF-2 pathway activation, consistent with its documented pro-angiogenic profile across multiple experimental models.
The angiogenic mechanism involves GHK-Cu acting as a chemoattractant for capillary endothelial cells. Raju et al. (1984), in an early characterisation of this property, demonstrated that GHK at low concentrations attracted capillary-building endothelial cells in chemotaxis assays. Subsequent work has linked this chemoattractant activity to VEGF pathway upregulation, with GHK-Cu-treated endothelial cell cultures showing enhanced tube formation in Matrigel assays — a standard in vitro model for angiogenesis research.
Wang et al. (2017), publishing in Wound Repair and Regeneration, demonstrated that GHK-Cu liposome formulations accelerated wound closure in mouse scald models through promotion of cell proliferation and angiogenesis, with treated wounds showing significantly higher capillary density than controls.
Antioxidant Mechanisms: SOD, Catalase, and Free Radical Quenching
GHK-Cu in mice protected their lung tissue from induced acute lung injury and suppressed the infiltration of inflammatory cells into the lung. GHK-Cu also increased superoxide dismutase (SOD) activity while decreasing TNF-1 and IL-6 production through the blocking activation of NF-κB's p65 and p38 MAPK.
GHK has been shown to be a quencher for hydroxyl and peroxyl radicals by ESR spectroscopy, with its ability to quench hydroxyl radicals much stronger than glutathione (GSH), making it a strong endogenous antioxidant.
Pretreatment of RAW 264.7 macrophage cells with GHK-Cu has been shown to significantly decrease reactive oxygen species (ROS) levels induced by lipopolysaccharide challenge, increase SOD activities and total glutathione, and decrease TNF-α and IL-6 production through suppression of NF-κB p65 and p38 MAPK signalling — both key regulatory pathways in the inflammatory cascade.
The antioxidant activity of GHK-Cu operates through two distinct mechanisms: direct free radical quenching by the peptide-copper complex itself, and indirect upregulation of endogenous antioxidant enzyme expression (SOD, catalase, glutathione peroxidase, ferritin). This combination of direct and indirect antioxidant activity gives GHK-Cu a broader protective profile than compounds acting through a single pathway alone.
Gene Expression Modulation: The Connectivity Map Findings
Perhaps the most striking finding in the GHK-Cu literature emerged not from classical pharmacology but from computational biology. Pickart, Vasquez-Soltero, and Margolina (2015), using the Broad Institute's Connectivity Map (CMap) database — a database developed at MIT and Harvard that maps how compounds alter gene activity across human cell lines — identified the scope of GHK-Cu's influence on human gene expression.
This revealed that GHK-Cu influences 31.2% of all human genes at a threshold of ≥50% expression change — an extraordinarily broad biological effect for a single molecule. The gene analysis also revealed that GHK-Cu downregulates 70% of cancer-related genes examined, including metastatic pathways, while upregulating DNA repair and caspase genes that eliminate damaged cells.
The pattern of gene modulation observed is characterised by upregulation of pathways associated with tissue repair, collagen synthesis, growth factor production, integrin expression, and antioxidant defence, alongside downregulation of inflammatory mediators, excess fibrinogen production, matrix metalloproteinase overexpression, and genes associated with cellular senescence. This coordinated shift led researchers to describe the gene expression profile as resembling a pattern reset toward younger, healthier tissue physiology — the same observation Pickart had made at the cellular level in his original 1973 liver experiments, now visible at the genomic level.
These findings have been published in BioMed Research International (Pickart et al., 2014, 2015), International Journal of Molecular Sciences (Pickart & Margolina, 2018, PMID: 29986520), and OBM Geriatrics (2018), among others. The Connectivity Map methodology is well-established and the database is widely used in drug discovery; the GHK-Cu gene expression data is methodologically sound, even if the biological interpretation continues to be refined in subsequent work.
Published Preclinical and In Vitro Study Findings
Wound Healing Research
Wound healing is the domain with the longest and most replicated evidence base for GHK-Cu, extending from Pickart's original 1970s work to controlled animal studies conducted through to the present decade.
Maquart et al. (1993), publishing in the Journal of Clinical Investigation, conducted in vivo studies in rat experimental wounds, demonstrating that topical GHK-Cu stimulated connective tissue accumulation, increased collagen deposition, and improved wound organisation compared to controls. This was one of the first controlled in vivo demonstrations of GHK-Cu's wound biology.
In rabbit experimental wound models, GHK alone or in combination with high-dose helium-neon laser improved wound contraction and formation of granular tissue, as well as increasing activity of antioxidant enzymes and stimulating blood vessel growth.
In rat wound models using peptide-incorporated collagen (PIC) dressings, the treated group displayed higher glutathione and ascorbic acid levels, better epithelialization, as well as increased synthesis of collagen and activation of fibroblasts and mast cells in wounds. In healthy rats, treatment of wounds with PIC increased collagen 9-fold.
Canapp et al. (2003), publishing in Veterinary Surgery, examined GHK-Cu in ischemic open wounds — wounds with impaired blood supply, which are notably difficult to heal. The study documented significant improvement in wound closure rates in GHK-Cu-treated animals compared to controls in this challenging wound model. Published preclinical data from rodent wound models consistently shows wound closure rate improvements in the range of 30–40% compared to vehicle-treated controls, with concurrent improvements in granulation tissue formation, angiogenesis, and healed tissue tensile strength.
Extracellular Matrix Research in Fibroblast Models
In cultured human dermal fibroblast studies, GHK-Cu treatment has been associated with 50–200% increases in collagen Type I, III, and IV synthesis depending on concentration and exposure duration — a range established across multiple independent research groups' replications of Pickart's foundational collagen synthesis work. A 2023 study in Biomolecules documented a 70% increase in collagen I production in GHK-Cu-treated dermal fibroblast cultures compared to controls, alongside concurrent reduction in MMP-1 expression — the enzyme responsible for collagen breakdown. This simultaneous upregulation of synthesis and downregulation of degradation illustrates GHK-Cu's balanced remodelling action.
Lung and COPD Research
Lung fibroblasts from COPD patients, which had impaired ability to contract and restructure collagen, were treated with GHK or TGF-β. Both molecules restored function of fibroblasts. They also had an elevated expression of integrin beta 1.
Campbell et al. (2012), publishing in Genome Medicine, used a 127-gene emphysema expression signature derived from patient lung tissue and demonstrated that GHK treatment reversed the pathological gene expression pattern toward a profile more consistent with healthy lung tissue. This study established GHK-Cu as a compound of interest in lung research beyond its dermal and wound healing origins.
In bleomycin-induced pulmonary fibrosis mouse models, GHK treatment showed reduced inflammatory cell infiltration and reduced interstitial thickness, alongside reduced TNF-α and IL-6 expression.
Skin Biology and Dermal Research
A facial cream containing GHK-Cu applied for 12 weeks to the facial skin of 71 women with mild to advanced signs of photoaging increased skin density and thickness, reduced fine lines and coarse wrinkles and mottled pigmentation. A parallel study found that GHK-Cu applied to thigh skin for 12 weeks improved collagen production in 70% of the women treated, in contrast to 50% treated with vitamin C cream and 40% treated with retinoic acid.
A 2023 IRB-approved clinical study by Yuvan Research Inc. of 21 women volunteers documented an average 28% increase in dermal collagen density measured by high-resolution ultrasound following 3 months of daily topical GHK-Cu gel application, with the upper quartile of volunteers showing 51% collagen density increase. This study, reported on EurekAlert (May 2023), represents one of the more rigorously documented human topical studies, though it is a small, single-arm trial without a control group and cannot be interpreted as definitive evidence of therapeutic efficacy.
Hair Follicle Research
GHK-Cu has been studied in dermal papilla cell models — the cells that control the hair growth cycle — where it has been documented to stimulate follicle cell proliferation, increase growth factor production (particularly VEGF and bFGF relevant to follicle vascularisation), and modulate the hair cycle phase duration. Research comparing GHK-Cu with minoxidil in alopecia models has suggested comparable effects on hair follicle size and anagen phase duration in certain experimental systems, though these are preclinical findings in controlled models and do not constitute clinical evidence.
Neurological Research
GHK-Cu's neurological research base is less extensive than its dermal and wound healing literature but is growing. Nerve growth factor (NGF) upregulation in neural cell models is the most frequently cited neurological finding: NGF is critical for the survival and maintenance of cholinergic neurons, and GHK-Cu treated neural cell cultures show NGF expression increases in published research. Tucker et al. (2023), examining intranasal GHK peptide in aging mouse models, reported improvements in resilience to cognitive decline measures compared to controls.
Plasma Levels, Age Decline, and Research Context
One element of the GHK-Cu research literature that is of particular interest to longevity researchers is the compound's endogenous age-related decline. Published data documents plasma GHK levels of approximately 200 ng/mL in individuals aged 20–25, declining to approximately 80 ng/mL by age 60 — a reduction of roughly 60% across the adult lifespan. This decline correlates temporally with the well-documented reduction in skin collagen density, wound healing capacity, and tissue repair efficiency that characterises biological ageing.
The relevance for preclinical research is straightforward: GHK-Cu is not a foreign compound but a molecule that already exists within the biological systems being studied. This endogenous origin gives it a distinctive safety and biocompatibility profile in laboratory contexts compared to synthetic xenobiotic compounds, and may partly explain why it has been studied across such a wide range of tissue systems without the toxicity concerns that complicate research with many other bioactive compounds.
Laboratory Reconstitution Protocol
GHK-Cu is supplied in lyophilised (freeze-dried) powder form in sealed glass vials, standardly at 50mg quantities. The following represents standard laboratory reconstitution practice. All handling should be conducted under appropriate sterile conditions.
A note on the copper complex. GHK-Cu is sensitive to conditions that disrupt the copper-peptide coordination bond. Strong acids — including glycolic acid, salicylic acid, and high-concentration ascorbic acid (L-vitamin C) — can displace the copper ion from the chelate complex, reducing the peptide's biological activity. Researchers should avoid combining GHK-Cu in solution with these compounds and should use neutral to mildly alkaline reconstitution media.
Required materials. Bacteriostatic water (sterile water with 0.9% benzyl alcohol preservative), or sterile phosphate-buffered saline (PBS) at pH 7.0–7.4 for experiments requiring a buffered environment. Syringes, needles of appropriate gauge, the sealed GHK-Cu vial.
Step 1 — Preparation. Allow the vial to reach ambient temperature before opening if refrigerated. Do not shake or vortex.
Step 2 — Volume calculation. Determine working concentration for your experimental protocol. A concentration of 1mg/ml is a common stock, achieved by adding 50ml of bacteriostatic water to a 50mg vial. For experiments using nanomolar concentrations — as many fibroblast studies employ — serial dilutions from this stock are performed. GHK-Cu shows biological activity in the picomolar-to-nanomolar range (10⁻¹² to 10⁻⁹ M) in some experimental systems, so accurate dilution is critical.
Step 3 — Reconstitution. Inject bacteriostatic water slowly against the interior wall of the vial. Do not direct the stream onto the lyophilised cake under pressure.
Step 4 — Dissolution. Swirl gently in a circular motion until fully dissolved. The solution will have a characteristic blue colour due to the copper chelate — this is expected and indicates intact GHK-Cu complex. A colourless solution may indicate loss of copper chelation and should be verified before use.
Step 5 — Visual inspection. The reconstituted solution should be clear and blue. Any cloudiness or particulate matter indicates the sample should not be used.
Step 6 — pH verification. For experiments where pH-sensitive effects are being studied, verify the reconstituted solution pH is within a physiologically neutral range (6.8–7.4). GHK-Cu is most stable within this range.
Storage Requirements
Lyophilised GHK-Cu (unreconstituted) should be stored at -20°C for long-term stability, where it remains stable for up to 24 months from manufacture as documented in the batch COA. Short-term storage at 2–8°C for up to 30 days is acceptable.
Once reconstituted, store at 2–8°C and use within 28 days. The blue colour of the reconstituted solution is a useful visual indicator of copper chelate integrity — if the solution becomes colourless during storage, the copper-peptide bond may have been disrupted and the sample's biological activity cannot be confirmed.
Protect from direct light at all stages — copper-containing compounds can undergo photochemical reactions. Store in amber glass or opaque containers wherever possible.
Do not expose to strong acid conditions — maintain pH above 5.5 to preserve copper chelation. Do not combine with L-ascorbic acid, glycolic acid, or salicylic acid in the same solution.
All Velyx Research Ltd shipments include cold-pack insulation to maintain cold chain during transit. Refrigerate upon receipt.
Purity Standards and COA Documentation
Research-grade GHK-Cu is characterised by HPLC purity assessed by reverse-phase HPLC, with 99%+ the standard for research-grade compounds. However, for GHK-Cu specifically, purity assessment has an additional dimension beyond simple peak area analysis: confirmation that the copper chelate complex is intact.
A compound measuring 99% pure by HPLC but with disrupted copper chelation is not the same compound as 99% pure intact GHK-Cu — its biological activity profile will differ. Researchers should therefore seek COA documentation that addresses both peptide purity (HPLC) and copper chelate integrity. Mass spectrometry (MS) can confirm the molecular weight of the copper complex (approximately 403.91 Da) distinguishing it from the unchelated tripeptide (340.37 Da).
Regulatory and Compliance Context (UK)
GHK-Cu is not a controlled substance under the Misuse of Drugs Act 1971 in the UK and is not scheduled under the Psychoactive Substances Act 2016. It is not classified as a Novel Food ingredient requiring FSA authorisation when sold for research rather than consumption purposes.
GHK-Cu has not received Marketing Authorisation from the MHRA and therefore cannot legally be sold, supplied, or marketed for human consumption or therapeutic use in the UK under the Human Medicines Regulations 2012. Velyx Research Ltd sells GHK-Cu exclusively as a research compound for laboratory use, with no claims made regarding therapeutic application in humans or animals.
GHK-Cu does hold regulatory status in some cosmetic contexts: it is listed in the EU Cosmetics Regulation inventory (CosIng) as an approved cosmetic ingredient, where it appears as glycyl histidyl lysine (GHK) in formulations intended for topical application at relevant concentrations. This cosmetic ingredient status applies to finished cosmetic product formulations and is distinct from the research compound context in which Velyx Research Ltd operates.
Key Published References
Campbell, J.D., McDonough, J.E., Zeskind, J.E., et al. (2012). A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine, 4(8), 67.
Canapp, S.O., Farese, J.P., Schultz, G.S., et al. (2003). The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 32(6), 515–523.
Dou, Y. et al. (2020). The potential of GHK as an anti-aging peptide. Aging Pathobiology and Therapeutics. PMC8789089.
Maquart, F.X., Bellon, G., Chaqour, B., et al. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 92(5), 2368–2376.
Maquart, F.X., Pickart, L., Laurent, M., Gillery, P., Monboisse, J.C., & Borel, J.P. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. PMID: 3169264.
Pickart, L., Vasquez-Soltero, J.M., & Margolina, A. (2015). GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics, 2(3), 236–247.
Pickart, L., Vasquez-Soltero, J.M., & Margolina, A. (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015, 648108. PMID: 26236730.
Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987. PMID: 29986520. PMC6073405.
Pickart, L., & Margolina, A. (2021). Modulation of gene expression in human breast cancer MCF7 and prostate cancer PC3 cells by the human copper-binding peptide GHK-Cu. OBM Genetics, 5(2), 128.
Tucker, M., Keely, A., Park, J.Y., et al. (2023). Intranasal GHK peptide enhances resilience to cognitive decline in aging mice.
Wang, X., Liu, B., Xu, Q., et al. (2017). GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair and Regeneration, 25(2), 270–278.
This article is provided for informational and educational purposes relating to published scientific research. It does not constitute medical advice. GHK-Cu is sold by Velyx Research Ltd for laboratory research use only and is not for human or veterinary consumption. Velyx Research Ltd makes no claims regarding therapeutic efficacy in humans.